文献速递泌尿生殖MRUS

基于MRI-超声融合穿刺验证前列腺影像报告和数据系统第2版在前列腺癌诊断中的应用

Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis.
PubMed 文献 · AJR Am J Roentgenol · 2017-07-13

前瞻性纳入295例连续患者共478个病灶,于2014年12月至2016年9月行多参数MRI及MRI-超声融合穿刺,以穿刺组织学为参考标准评估PI-RADS第2版对临床显著前列腺癌的诊断效能。全腺体总体评分≥4分时准确率82.2%,敏感度90.0%、特异度80.1%;≥3分时准确率68.6%,敏感度94.6%、特异度58.7%。结论认为PI-RADS第2版整体诊断性能良好。

要点

  • PI-RADS第2版总体评分诊断临床显著前列腺癌全腺体准确率82.2%(393/478)。
  • 以≥4分为 cutoff,敏感度90.0%(90/100)、特异度80.1%(303/378)。
  • 外周带准确率84.7%(301/355),移行带准确率74.7%(92/123)。

核心结论

  • PI-RADS第2版对临床显著前列腺癌的诊断整体性能良好。

研究设计与样本

  • 前瞻性研究,纳入295例连续患者共478个病灶。
  • 患者于2014年12月至2016年9月行多参数MRI及后续MRI-超声融合穿刺。
  • 由一名放射科医生采用PI-RADS第2版总体评分评估病灶。
  • 以MRI-超声融合穿刺标本的组织学检查为参考标准。

诊断标准与关键数值

  • 全腺体总体评分≥4分:准确率82.2%(393/478),敏感度90.0%(90/100),特异度80.1%(303/378),阳性预测值83.3%(90/108),阴性预测值81.8%(303/370)。
  • 应用任意总体评分≥3分:准确率68.6%(328/478),敏感度94.6%(124/131),特异度58.7%(204/347),阳性预测值51.6%(124/240),阴性预测值85.7%(204/238)。
  • 外周带总体评分准确率84.7%(301/355),移行带总体评分准确率74.7%(92/123)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of our study was to prospectively assess Prostate Imaging Reporting and Data System (PI-RADS) version 2 using an MRI-ultrasound fusion biopsy.

SUBJECTS AND METHODS: This study included 295 consecutive patients with 478 lesions who underwent multiparametric MRI and subsequent MRI-ultrasound fusion biopsy between December 2014 and September 2016. Lesions were assessed by using an overall score of PI-RADS version 2. One radiologist assessed the presence or absence of clinically significant prostate cancer in the whole gland and in subgroups of the peripheral zone and transition zone by using cutoff values of ≥ 4 and ≥ 3. Histologic examination of MRI-ultrasound fusion biopsy specimens was used as the reference standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated to assess the utility of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer.

RESULTS: The overall PI-RADS version 2 scores showed an accuracy of 82.2% (393/478) for the whole gland, with a cutoff value of ≥ 4 granting sensitivity of 90.0% (90/100), specificity of 80.1% (303/378), PPV of 83.3% (90/108), and NPV of 81.8% (303/370). The overall scores showed accuracies of 84.7% (301/355) in the peripheral zone and 74.7% (92/123) in the transition zone. When we applied an arbitrary overall score of ≥ 3, accuracy was 68.6% (328/478), sensitivity was 94.6% (124/131), specificity was 58.7% (204/347), PPV was 51.6% (124/240), and NPV was 85.7% (204/238).

CONCLUSION: PI-RADS version 2 has an overall good performance for the diagnosis of clinically significant prostate cancer.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Kim SH, Choi MS, Kim MJ, et al. Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis. AJR Am J Roentgenol. 2017. PMID: 28705064. doi:10.2214/AJR.16.17629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。